SCHEMBL13041789

SCHEMBL13041789

Cc1cc(NC(=O)Nc2ccc(-c3cc(C4CC4)nc4c3c(N)nn4C)cc2)ccc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.54
KIT P10721 15/20 0.54
CSF1R P07333 13/20 0.54
FLT3 P36888 13/20 0.54
BLK P51451 12/20 0.54
FLT4 P35916 12/20 0.54
LCK P06239 11/20 0.54
FLT1 P17948 11/20 0.54
LYN P07948 11/20 0.54
SRC P12931 8/20 0.54
ABL1 P00519 3/20 0.54
FYN P06241 6/20 0.49
CDK19 Q9BWU1 1/20 0.49
DYRK3 O43781 4/20 0.48
ROCK2 O75116 4/20 0.48
MAP4K4 O95819 4/20 0.48
RET P07949 4/20 0.48
FGFR1 P11362 4/20 0.48
RPS6KB1 P23443 4/20 0.48
EPHA2 P29317 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041762 0.93 KDR (0.56) KDRKITCSF1RFLT3BLK
SCHEMBL13041757 0.90 KIT (0.52) KDRKITCSF1RFLT3BLK
SCHEMBL13041781 0.89 KIT (0.58) KDRKITCSF1RFLT3BLK
SCHEMBL13041792 0.89 KDR (0.65) KDRKITCSF1RFLT3BLK
SCHEMBL13041799 0.89 KDR (0.70) KDRKITCSF1RFLT3BLK
SCHEMBL13041805 0.89 KDR (0.52) KDRKITCSF1RFLT3BLK
SCHEMBL13041768 0.88 CSF1R (0.52) KDRKITCSF1RFLT3BLK
SCHEMBL13041761 0.88 KDR (0.54) KDRKITCSF1RFLT3BLK
SCHEMBL13041753 0.88 KDR (0.54) KDRKITCSF1RFLT3BLK
SCHEMBL13041752 0.88 KDR (0.54) KDRKITCSF1RFLT3BLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
WO-2007144202-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO disclosed
EP-1867647-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK KDR 1/4885KIT 22/4885CSF1R 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.